

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

☒ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Menzel Garry E</u> (Last) (First) (Middle) <u>C/O TCR2 THERAPEUTICS</u> <u>100 BINNEY STREET</u> (Street) <u>CAMBRIDGE</u> <u>MA</u> <u>02142</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>TCR2 THERAPEUTICS INC. [TCRR]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>President and CEO</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>06/01/2023</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/01/2023		D ⁽¹⁾		132,729	D	(2)	0	I	See Footnote ⁽³⁾
Common Stock	06/01/2023		D ⁽¹⁾		132,730	D	(2)	0	I	See Footnote ⁽⁴⁾
Common Stock	06/01/2023		D ⁽¹⁾		138,871	D	(2)	0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$0.74	06/01/2023		D ⁽¹⁾⁽⁵⁾		138,031	(5)	(5)	Common Stock	138,031	\$0.00	0	D	
Stock Option (Right to Buy)	\$5.88	06/01/2023		D ⁽¹⁾⁽⁵⁾		433,037	(5)	(5)	Common Stock	433,037	\$0.00	0	D	
Stock Option (Right to Buy)	\$5.21	06/01/2023		D ⁽¹⁾⁽⁵⁾		305,800	(5)	(5)	Common Stock	305,800	\$0.00	0	D	
Stock Option (Right to Buy)	\$0.97	06/01/2023		D ⁽¹⁾⁽⁵⁾		238,008	(5)	(5)	Common Stock	238,008	\$0.00	0	D	
Restricted Stock Unit	(6)(7)	06/01/2023		D ⁽¹⁾⁽⁶⁾⁽⁷⁾		3,241	(6)(7)	(6)(7)	Common Stock	3,241	\$0.00	0	D	
Restricted Stock Unit	(6)(7)	06/01/2023		D ⁽¹⁾⁽⁶⁾⁽⁷⁾		15,120	(6)(7)	(6)(7)	Common Stock	15,120	\$0.00	0	D	
Restricted Stock Unit	(6)(7)	06/01/2023		D ⁽¹⁾⁽⁶⁾⁽⁷⁾		23,165	(6)(7)	(6)(7)	Common Stock	23,165	\$0.00	0	D	
Restricted Stock Unit	(6)(7)	06/01/2023		D ⁽¹⁾⁽⁶⁾⁽⁷⁾		39,681	(6)(7)	(6)(7)	Common Stock	39,681	\$0.00	0	D	

Explanation of Responses:

1. This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

2. At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares").

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.